56 results about "Inflammatory marker" patented technology

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment of stress-mediated depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers is increased or abnormal in said patient. The present invention also relates to a method for the treatment of depression or the amelioration of one or more depressive symptoms comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the clinical presentation of one or more symptoms of depression are the physiological effect of a general medical condition. Furthermore the present also relates to a method for testing the therapeutic effectiveness of a compound in the treatment of depression or reducing the symptoms of depression comprising measuring the amount of one or more inflammatory markers in a sample from a patient before said compound is administered to the patient and comparing with the amount of said one or more inflammatory markers in a sample from the same patient after administration of said compound to the patient.

The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

A method of treating a human subject which is effected by intermittent breathing cycle-coordinated pulse delivery inhalation of gaseous nitric oxide at a concentration of at least 160 ppm, or at a load per cycle of 80 ppm-hour, is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

The invention provides a liquid-phase chip kit for detecting inflammatory markers in gingival crevicular fluid. The liquid-phase chip kit comprises (1) a 3-plex-wrapped microsphere, (2) a 3-plex biotin marking detection antibody, and (3) streptavidin phycoerythrin, wherein the 3-plex-wrapped microsphere comprises encoded microspheres which are respectively coated with IL-1beta capturing antibodies, IL-6 capturing antibodies and Osteocalcin capturing antibodies and have different colors, and the 3-plex biotin marking detection antibody comprises an IL-1beta detection antibody, an IL-6 detection antibody and an Osteocalcin detection antibody which are marked by biotin. The invention also provides a preparation method for the kit. The liquid-phase chip kit for detecting the inflammatory markers in the gingival crevicular fluid has the advantages of high flux, parallel multi-index detection, quickness and accuracy in detection, low cost and the like. Experiments show that the forecast accuracy of the incidence rate of adverse reactions and inflammatory risks of tissues around teeth can reach more than 90 percent after a fixed partial denture is repaired through the adoption of the kit provided by the invention.

The present invention relates to a method for establishing a diagnosis if an individual has suffered from or a prognosis if an individual is at risk of suffering from a coronary heart event, which method comprises determining the concentration of sCD40L in a body fluid of the individual; determining the concentration of a proximal inflammatory marker, preferably PAPP-A or Lp-PLA2 comparing the values obtained with reference values; and establishing the diagnosis or the prognosis in respect to the cardiovascular event. The combination according to the invention can be used with further markers selected from further inflammatory markers, anti-inflammatory markers and/or neurohumoral markers.

The present invention provides a composition for down-regulating pro-inflammatory markers. The composition comprises boswellic acid fraction and polysaccharide faction obtained from Boswellia species at specific concentrations showing enhancement in their activity as compared to boswellic acid fraction and the polysaccharide fraction alone. The invention further comprises use of polysaccharide fraction individually or in combination with boswellic acid fraction for inhibition of PGE2.

The invention provides a method and a kit for simultaneously detecting four inflammatory markers. The kit for simultaneously detecting four inflammatory markers comprises: a microsphere reagent and abiotinylation antibody; wherein the microsphere reagent comprises four types of encoded microspheres, the four types of encoded microspheres respectively correspond to specific antibodies coupled to the four inflammatory markers, and the four types of inflammatory markers are PCT, IL-6, CRP and SAA; and the biotinylation antibody comprises detection antibodies for the four inflammatory markers, and the detection antibodies are labeled with fluorescein. The kit provided by the invention can simultaneously detect the concentrations of the four indicators of PCT, IL-6, CRP and SAA in the serum, thereby realizing the quantitative detection of the indicators, having high efficiency and reducing the cost, furthermore, the detection concentration range is wide, the required sample volume is small, and the variable coefficient of intra-batch and inter-batch experiments is small.

The invention belongs to the field of clinical medicine detection, and discloses a quality control product of an inflammatory marker and a preparation method of the quality control product. The quality control product of the inflammation marker is composed of a matrix liquid and an inflammation marker component, wherein the matrix liquid is composed of a matrix, a 5-100 mmol/L buffer agent, a 0.01-5 g/L protein protective agent, a 5-100 g/L saccharide and a 0.05-5 g/L preservative; the inflammation marker comprises the following components: procalcitonin, C reactive protein, serum amyloid protein A, myeloperoxidase, interleukin-6 and lipoprotein related phospholipase. The quality control product of the inflammatory marker contains a plurality of inflammatory markers, so that the joint detection of different inflammatory items is realized. Meanwhile, commercial human serum or plasma is adopted as a matrix, the channel source is stable, large-batch production can be achieved, the clinical sample conformity degree is high, the universality is high, the matrix effect can be reduced to the maximum extent, and the uniformity, stability and other performance are good.

Disclosed is a method of determining which medication is to be applied in a remodeling process of a subject after a myocardial infarction, the method comprising determining an amount of a natriuretic peptide, a cardiac troponin, and an inflammatory marker in a sample from the subject and initiating a remodeling in the subject, wherein the medication to be applied in the remodeling is selected according to the level of the peptides determined. Also disclosed is a method of monitoring the remodeling, wherein further steps include again determining an amount of the natriuretic peptide, the cardiac troponin, and the inflammatory marker in a sample from the subject, calculating the difference between the values from the first and second measurements, and assessing remodeling success from the data obtained.

Disclosed herein are compositions comprising tea derived components which are useful in decreasing elevated blood pressures, lowering LDL and/or lowering inflammatory markers of cardiovascular disease. Specifically exemplified herein are compositions comprising predetermined amounts of L-theanine and EGCG, and methods of using same to improve cardiovascular health.

The invention discloses application of sipunculid peptide to preparation of gestational period hypertension treatment or prevention products. The amino acid sequence of the sipunculid peptide is His-Thr-Arg-Asp-Gly. The sipunculid peptide can effectively reduce the blood pressure and the urine protein of a mouse with gestational period hypertension caused by L-nitrous acid L-arginine methyl ester,inhibit the increase of the oxidative stress index of the mouse with gestational period hypertension and can also reduce the up-regulation of inflammatory marker molecules. The sipunculid peptide isa compound capable of effectively intervening the gestational period hypertension diseases generated during the woman gestational period. The sipunculid peptide has high use safety on users-pregnant women with gestational period hypertension diseases, and has the characteristics of no toxicity and low side effect. The sipunculid peptide can be widely used in pharmacy, heath care products and food,and is used for prevention and treatment.

The invention relates to a method for detecting inflammatory markers and a kit for detecting inflammatory markers to solve the problems of narrow detection range, low sensitivity, manual operation andhigh requirements on climatic conditions for detecting inflammatory markers in the prior art. The method for detecting inflammatory markers and the kit for detecting inflammatory markers provided bythe invention have wider detection range, higher accuracy and sensitivity, can simultaneously detect SAA, PCT and CRP, and are convenient in operation and stable in detection result.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.